ZA200102185B - Benzamide derivatives and their use as cytokine inhibitors. - Google Patents
Benzamide derivatives and their use as cytokine inhibitors. Download PDFInfo
- Publication number
- ZA200102185B ZA200102185B ZA200102185A ZA200102185A ZA200102185B ZA 200102185 B ZA200102185 B ZA 200102185B ZA 200102185 A ZA200102185 A ZA 200102185A ZA 200102185 A ZA200102185 A ZA 200102185A ZA 200102185 B ZA200102185 B ZA 200102185B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- alkylamino
- alkoxy
- amino
- alkanoylamino
- Prior art date
Links
- 108090000695 Cytokines Proteins 0.000 title claims description 20
- 102000004127 Cytokines Human genes 0.000 title claims description 20
- 239000003112 inhibitor Substances 0.000 title description 6
- 150000003936 benzamides Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 249
- 125000003282 alkyl amino group Chemical group 0.000 claims description 183
- -1 cyano, mercapto, nitro, amino, carboxy, carbamoyl Chemical group 0.000 claims description 135
- 125000003545 alkoxy group Chemical group 0.000 claims description 107
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 82
- 125000001424 substituent group Chemical group 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- 150000001408 amides Chemical class 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000001589 carboacyl group Chemical group 0.000 claims description 8
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 8
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000005239 aroylamino group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 9
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000005864 Sulphur Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- SNJXAEOTSRFPGO-UHFFFAOYSA-N 2-morpholin-4-ylpyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(N2CCOCC2)=C1 SNJXAEOTSRFPGO-UHFFFAOYSA-N 0.000 claims 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- QWYCXSDHMJCTLX-UHFFFAOYSA-N n-[3-[[4-(diethylaminomethyl)benzoyl]amino]-4-methylphenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=CC(CN(CC)CC)=CC=C1C(=O)NC1=CC(NC(=O)C=2C=C(N=CC=2)N2CCOCC2)=CC=C1C QWYCXSDHMJCTLX-UHFFFAOYSA-N 0.000 claims 1
- RXZIRKRDXDRFAA-UHFFFAOYSA-N n-[3-[[4-[(3-hydroxypyrrolidin-1-yl)methyl]benzoyl]amino]-4-methylphenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC(=O)C=2C=CC(CN3CC(O)CC3)=CC=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 RXZIRKRDXDRFAA-UHFFFAOYSA-N 0.000 claims 1
- QSNZIHAHDWFKEB-UHFFFAOYSA-N n-[3-[[4-[[3-(dimethylamino)propyl-methylamino]methyl]benzoyl]amino]-4-methylphenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=CC(CN(C)CCCN(C)C)=CC=C1C(=O)NC1=CC(NC(=O)C=2C=C(N=CC=2)N2CCOCC2)=CC=C1C QSNZIHAHDWFKEB-UHFFFAOYSA-N 0.000 claims 1
- LAOPKCSMEAUUDY-UHFFFAOYSA-N n-[4-methyl-3-[(3-pyrrolidin-3-yloxybenzoyl)amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC(=O)C=2C=C(OC3CNCC3)C=CC=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 LAOPKCSMEAUUDY-UHFFFAOYSA-N 0.000 claims 1
- XVWKPEDUAVMRRU-UHFFFAOYSA-N n-[4-methyl-3-[[3-(1-methylazepan-4-yl)oxybenzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1CN(C)CCCC1OC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3C=C(N=CC=3)N3CCOCC3)C=2)C)=C1 XVWKPEDUAVMRRU-UHFFFAOYSA-N 0.000 claims 1
- FUYPFZDBJVTCNE-UHFFFAOYSA-N n-[4-methyl-3-[[3-(piperazin-1-ylmethyl)benzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC(=O)C=2C=C(CN3CCNCC3)C=CC=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 FUYPFZDBJVTCNE-UHFFFAOYSA-N 0.000 claims 1
- YVGHLOWUEYFJIJ-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(3-pyrrolidin-1-ylpropylamino)methyl]benzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC(=O)C=2C=C(CNCCCN3CCCC3)C=CC=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 YVGHLOWUEYFJIJ-UHFFFAOYSA-N 0.000 claims 1
- DJGVVEBKFSLTAC-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3ON=CC=3)C=2)C)=C1 DJGVVEBKFSLTAC-UHFFFAOYSA-N 0.000 claims 1
- LMGRQKNWVZHCFE-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]-2-(3-methylpiperidin-1-yl)pyridine-4-carboxamide Chemical compound C1C(C)CCCN1C1=CC(C(=O)NC=2C=C(NC(=O)C=3C=C(CN4CCN(C)CC4)C=CC=3)C(C)=CC=2)=CC=N1 LMGRQKNWVZHCFE-UHFFFAOYSA-N 0.000 claims 1
- SUDGKXVNLSNRAZ-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3C=C(N=CC=3)N3CCOCC3)C=2)C)=C1 SUDGKXVNLSNRAZ-UHFFFAOYSA-N 0.000 claims 1
- FWWIHDABCUSHCT-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]-2-pyrrolidin-1-ylpyridine-4-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3C=C(N=CC=3)N3CCCC3)C=2)C)=C1 FWWIHDABCUSHCT-UHFFFAOYSA-N 0.000 claims 1
- NZDTURVTBGFCJP-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]dibenzofuran-4-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3C=4OC5=CC=CC=C5C=4C=CC=3)C=2)C)=C1 NZDTURVTBGFCJP-UHFFFAOYSA-N 0.000 claims 1
- UDSRUJPSZUHVOI-UHFFFAOYSA-N n-[4-methyl-3-[[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]furan-2-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3OC=CC=3)C=2)C)=C1 UDSRUJPSZUHVOI-UHFFFAOYSA-N 0.000 claims 1
- XLWOLGYQFOJFCG-UHFFFAOYSA-N n-[4-methyl-3-[[3-[2-(1-methylpyrrolidin-2-yl)ethoxy]benzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound CN1CCCC1CCOC1=CC=CC(C(=O)NC=2C(=CC=C(NC(=O)C=3C=C(N=CC=3)N3CCOCC3)C=2)C)=C1 XLWOLGYQFOJFCG-UHFFFAOYSA-N 0.000 claims 1
- RBWVIIJQUSKMOF-UHFFFAOYSA-N n-[4-methyl-3-[[4-(morpholin-4-ylmethyl)benzoyl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide Chemical compound C1=C(NC(=O)C=2C=CC(CN3CCOCC3)=CC=2)C(C)=CC=C1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 RBWVIIJQUSKMOF-UHFFFAOYSA-N 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108700012920 TNF Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Description
BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
This invention concerns certain amide derivatives which are useful as inhibitors of cytokine mediated disease. The invention also concerns processes for the manufacture of the ] 5 amide derivatives of the invention, pharmaceutical compositions containing them and their use in therapeutic methods, for example by virtue of inhibition of cytokine mediated disease.
The amide derivatives disclosed in the present invention are inhibitors of the production of cytokines such as Tumour Necrosis Factor (hereinafter TNF), for example
TNFa. and various members of the interleukin (hereinafter IL) family, for example IL-1, IL-6 and IL-8. Accordingly the compounds of the invention will be useful in the treatment of diseases or medical conditions in which excessive production of cytokines occurs, for example excessive production of TNFa or IL-1. It is known that cytokines are produced by a wide variety of cells such as monocytes and macrophages and that they give rise to a variety of physiological effects which are believed to be important in disease or medical conditions such as inflammation and immunoregulation. For example, TNFa and IL-1 have been implicated in the cell signalling cascade which is believed to contribute to the pathology of disease states such as inflammatory and allergic diseases and cytokine-induced toxicity. It is also known that, in certain cellular systems, TNFa production precedes and mediates the production of other. cytokines such as IL-1.
Abnormal levels of cytokines have also been implicated in. for example, the production of physiologically-active eicosanoids such as the prostaglandins and leukotrienes, the stimulation of the release of proteolytic enzymes such as collagenase, the activation of the immune system, for example by stimulation of T-helper cells, the activation of osteoclast activity leading to the resorption of calcium, the stimulation of the release of proteoglycans from, for example, cartilage, the stimulation of cell proliferation and to angiogenesis. a Cytokines are also believed to be implicated in the production and development of disease states such as inflammatory and allergic diseases, for example inflammation of the
E joints (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis, Crohn’s disease and gastritis), skin disease (especially psoriasis. eczema and dermatitis) and - respiratory disease (especially asthma. bronchitis. allergic rhinitis and adult respiratory distress syndrome), and in the production and development of various cardiovascular and cerebrovascular disorders such as congestive heart disease, myocardial infarction, the formation of atherosclerotic plaques, hypertension, platelet aggregation, angina, stroke, reperfusion injury, vascular injury including restenosis and peripheral vascular disease, and, for example, various disorders of bone metabolism such as osteoporosis (including senile and postmenopausal osteoporosis), Paget's disease, bone metastases, hypercalcaemia, hyperparathyroidism, osteosclerosis, osteoperosis and periodontitis, and the abnormal changes in bone metabolism which may accompany rheumatoid arthritis and osteoarthritis. Excessive cytokine production has also been implicated in mediating certain complications of bacterial, fungal and/or viral infections such as endotoxic shock, septic shock and toxic shock syndrome and in mediating certain complications of CNS surgery or injury such as neurotrauma and ischaemic stroke. Excessive cytokine production has also been implicated in mediating or exacerbating the development of diseases involving cartilage or muscle resorption, pulmonary fibrosis, cirrhosis, renal fibrosis, the cachexia found in certain chronic diseases such as malignant disease and acquired immune deficiency syndrome (AIDS), tumour invasiveness and tumour metastasis and multiple sclerosis.
Evidence of the central role played by TNFa in the cell signalling cascade which gives rise to rheumatoid arthritis is provided by the efficacy in clinical studies of antibodies of
TNFa (The Lancet, 1994, 344, 1125 and British Journal of Rheumatology, 1995, 34, 334).
Thus cytokines such as TNFa and IL-1 are believed to be important mediators of a considerable range of diseases and medical conditions. Accordingly it is expected that inhibition of the production of and/or effects of these cytokines will be of benefit in the prophylaxis, control or treatment of such diseases and medical conditions.
Without wishing to imply that the compounds disclosed in the present invention possess pharmacological activity only by virtue of an effect on a single biological process, it \ is believed that the compounds inhibit the effects of cytokines by virtue of inhibition of the enzyme p38 kinase. p38 kinase, otherwise known as cytokine suppressive binding protein . (hereinafter CSBP) and reactivating kinase (hereinafter RK), is a member of the mitogen- activated protein (hereinafter MAP) kinase family of enzymes which is known to be activated by physiological stress such as that induced by ionising radiation, cytotoxic agents, and toxins, for example endotoxins such as bacterial lipopolysaccharide, and by a variety of agents
: such as the cytokines, for example TNFa and IL-1. It is known that p38 kinase phosphorylates certain intracellular proteins which are involved in the cascade of enzymatic steps which leads to the biosynthesis and excretion of cytokines such as TNFa and IL-1.
Known inhibitors of p38 kinase have been reviewed by G J Hanson in Expert Opinions on
Therapeutic Patents, 1997, 7, 729-733. p38 kinase is known to exist in isoforms identified as p38a and p38f.
The compounds disclosed in the present invention are inhibitors of the production of cytokines such as TNF, in particular of TNFa, and various interleukins, in particular IL-1.
According to one aspect of the present invention there is provided a compound of the
Formula (Rp 5 F (R?), pat ‘ : Re H &F 0 ) N= 2
H (CH,),—Q I wherein R’ is (1-6C)alkyl or halogeno; “mis0,1,2o0r3;
R'is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)alkylenedioxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsuiphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]Jamino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,
N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (1-6C)alkanoylamino,
N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonyiamino, . N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino- . (1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl- (1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl,
N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy,
(1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl- (1-6C)alkoxy, N.N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, halogeno- (2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1 -6C)alkoxy-(2-6C)alkylamino, cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbony!- - (1-6C)alkylamino, carbamoyl-(1-6C)alkylamino, N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino,
N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]Jamino-(2-6C)alkylamino,
N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino,
N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino,
N-(1-6C)alkyl-carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-(1 -6C)alkoxycarbonyl- (1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-(1-6C)alkylamino, N-(1 -6C)alkyl-
N-(1-6C)alkylcarbamoyi-(1-6C)alkylamino, N-(1-6C)alkyl-N,N-di-[(1 -6C)alkyl]carbamoy!l- (1-6C)alkylamino, N-(1 -6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino- (2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy- (2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoyl-(2-6C)alkanoylamino,
N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino, N,N-di-[(1 -6C)alkyljcarbamoyl- (2-6C)alkanoylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino or di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino, or R' is aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino,
N-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino, N-(1-6C)alkyl-aryl-(1-6C)alkylamino, aroylamino, arylsulphonylamino, N-arylsulphamoyl, aryl-(2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino, . N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1 -6C)alkylamino, N-(1-6C)alkyl-heteroaryl- (1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino,
N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heterocyclyl, heterocyclyl- (1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1 -6C)alkoxy, heterocyclylamino, N-(1-6C)alkyl- heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino,
N-heterocyclylsulphamoy! or heterocyclyl-(2-6C)alkanoylamino, and wherein any aryl, heteroaryl or heterocyclyl group in a R' substituent may optionally bear 1 or 2 substituents selected from hydroxy. halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl,
N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]jcarbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkylJamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, ~ (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alky!, (1-6C)alkylamino- (1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl; pis0,1or2;
R? is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, (1-6C)alkoxycarbonyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino or di-[(1-6C)alkyl}amino;
R* is amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, amino-(1-6C)alkyl, (1-6C)alkylamino- (1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, amino-(2-6C)alkoxy, (1-6C)alkylamino- 4 (2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(2-6C)alkylamino, . 15 (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]Jamino-(2-6C)alkylamino,
N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, . N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino or di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino, or R* is heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino, N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino,
N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heteroaryl-(1-6C)alkoxy-(1-6C)alkyl, heteroaryl-(1-6C)alkylamino-(1-6C)alkyl,
N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino-(1-6C)alkyl, heterocyclyl, heterocyclyl- (1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy, heterocyclylamino, N-(1-6C)alkyl- heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino, : N-heterocyclylsulphamoyl, heterocyclyl-(2-6C)alkanoylamino, heterocyclyl-(1-6C)alkoxy- (1-6C)alkyl, heterocyclyl-(1-6C)alkylamino-(1-6C)alkyl or N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino-(1-6C)alkyl, and wherein any of the R* substituents defined hereinbefore which comprises a CH, group which is attached to 2 carbon atoms or a CH, group which is attached to a carbon atom may optionally bear on each said CH, or CH, group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and heterocyclyl, and wherein any aryl, heteroaryl or heterocyclyl group in a R* substituent may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyi, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl}amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl; qis0, 1,2, 3 or 4; and
Q’ is heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino,
N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino, N-(1-6C)alkyl-heteroaryl- (1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino,
N-heteroarylsulphamoy! or heteroaryl-(2-6C)alkanoylamino and Q” is optionally substituted with 1, 2 or 3 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkyny], (1-6C)alkoxy, (1-3C)alkylenedioxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,
N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,
N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl- (1-6C)alkanesulphonylamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy- (1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl, carbamoy!-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl,
N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl- (1-6C)alkoxy, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl}amino-(2-6C)alkoxy, halogeno- (2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, cyano-
(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl-(1-6C)alkylamino, carbamoyl-(1-6C)alkylamino, N~(1-6C)alkylcarbamoyl-(1-6C)alkylamino,
N,N-di-[(1-6C)alkyl]carbamoyl-~(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino. di-[(1-6C)alkylJamino-(2-6C)alkylamino,
N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino, ~
N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino,
N-(1-6C)alkyl-carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl- (1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-(1-6C)alkylamino, N-(1-6C)alky!-
N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoy!- (1-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino- (2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy- (2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino, iv (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoyl-(2-6C)alkanoylamino, d 15 N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino, N,N-di-[(1-6C)alkyl]carbamoyI- (2-6C)alkanoylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino, di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino, aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, * aryloxy, arylamino, N-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino, N-(1-6C)alkyl-aryl- : * (1-6C)alkylamino, aroylamino, arylsulphonylamino, N-arylsulphamoyl, aryl- (2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl. heteroaryloxy, heteroaryl- (1-6C)alkoxy, heteroarylamino, N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino,
N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heteroaryl-(1-6C)alkoxy-(1-6C)alkyl, heteroaryl-(1-6C)alkylamino-(1-6C)alkyl,
N-(1-6C)alkyl-heteroaryi-(1-6C)alkylamino-(1-6C)alkyl, heterocyclyl, heterocyclyl- : (1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy, heterocyclylamino, N-(1 -6C)alkyl- heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino,
N-heterocyclylsulphamoyl, heterocyclyl-(2-6C)alkanoylamino, heterocyclyl-(1-6C)alkoxy- (1-6C)alkyl, heterocyclyl-(1-6C)alkylamino-(1-6C)alkyl and N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino-(1-6C)alkyl,
Claims (20)
1. An amide derivative of the Formula I (Rm o R (R23), ~ R4 H Oo N= 2 S H (CH), —Q I wherein R’ is (1-6C)alkyl or halogeno; mis0,1,2o0r3; R'is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)alkylenedioxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyi, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, halogeno-(1-6C)alky!l, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino- (1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl- (1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyi-(1-6C)alky], N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy, N-(1-6C)alkyicarbamoyl- (1-6C)alkoxy, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy,
. (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, halogeno- (2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1 -6C)alkoxy-(2-6C)alkylamino, - cyano-(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl- (1-6C)alkylamino, carbamoyl-(1-6C)alkylamino, N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyljamino-(2-6C)alkylamino, N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino,
N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino,
+ N-(1-6C)alkyl-carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl- (1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl- N-(1-6C)alkylcarbamoyl-(1-6C)alkvlamino, N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyl-
(1-6Cjalkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylaniino- (2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy-
(2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoy!-(2-6C)alkanoylamino,
N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino, N,N-di-[(1-6C)alkyl]carbamoyl- (2-6C)alkanoylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino or di-[(1-6C)alkyl]amino-(2-6C)alkanoylamino, or R' is aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino, N-(1-6C)alkyl-arylamino, aryl-(1-6C)alkylamino, N-(1-6C)alkyl-aryl-(1-6C)alkylamino,
aroylamino, arylsulphonylamino, N-arylsulphamoyl, aryl-(2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino, N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino, N-(1-6C)alkyl-heteroaryl- (1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heterocyclyl, heterocyclyl-
(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy. heterocyclylamino, N-(1-6C)alkyl- heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclyisulphonylamino, N-heterocyclylsulphamoyl or heterocyclyl-(2-6C)alkanoylamino, and wherein any aryl, heteroaryl or heterocyclyl group in a R' substituent may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl,
“ N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoy]l. (2-6C)alkanoy!, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino- (1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl; pis0,1or2;
R’ is hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, - (1-6C)alkoxycarbonyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino or di-[(1-6C)alkyl]Jamino; R* is amino, (1-6C)alkylamino, di-[(1-6C)alkyl}amino, amino-(1-6C)alkyl, (1-6C)alkylamino- (1-6C)alkyl, di-[(1-6C)alkyllamino-(1-6C)alkyl, amino-(2-6C)alkoxy, (1-6C)alkylamino- ~ (2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino, amino-(2-6C)alkanoylamino,
(1-6C)alkylamino-(2-6C)alkanoyviamino or di-{(1-6C)alkyl]amino-(2-6C)alkanoylamino, or Ris heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino, N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino, N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino,
heteroaryl-(1-6C)alkoxy-(1-6C)alkyl, heteroaryl-(1-6C)alkylamino-(1-6C)alkyl, N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino-(1-6C)alkyl, heterocyclyl, heterocyclyl- (1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy, heterocyclylamino, N-(1-6C)alkyl- heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino,
N-heterocyclylsulphamoyl, heterocyclyl-(2-6C)alkanoylamino, heterocyclyl-(1-6C)alkoxy- (1-6C)alkyl, heterocyclyl-(1-6C)alkylamino-(1-6C)alkyl or N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino-(1-6C)alkyl, and wherein any of the R* substituents defined hereinbefore which comprises a CH, group which is attached to 2 carbon atoms or a CH, group which is attached to a carbon atom may optionally bear on each said CH, or CH, group a substituent selected from hydroxy, amino,
\ (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and heterocyclyl, and wherein any aryl, heteroaryl! or heterocyclyl group in a R* substituent may optionally bear . 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkylJamino, halogeno-(1-6C)alkyl,
hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, + (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, aryl and aryl-(1-6C)alkyl; qis0,1,2,3 0r4; and Q’ is heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heteroarylamino,
__ _..5 N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino, N-(1-6C)alkyl-heteroaryl- = (1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl or heteroaryl-(2-6C)alkanoylamino and Q’ is optionally substituted with 1, 2 or 3 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-3C)alkylenedioxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkylJamino, (1-6C)alkoxycarbonyl, : N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoy]l, (2-6C)alkanoyloxy, (1-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,
- N,N-di-[(1-6C)alkyl]sulphamoy]l, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-
Eo “ 15 (1-6C)alkanesulphonylamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy- (1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,
SS di-[(1-6C)alkyl}amino-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl,
Lk carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl,
- - N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alky!, halogeno-(2-6C)alkoxy, hydroxy-(2-6C)alkoxy,
(1-6C)alkoxy-(2-6C)alkoxy, cyano-(1-6C)alkoxy, carboxy-(1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkoxy, carbamoyl-(1-6C)alkoxy, N-(1-6C)alkylcarbamoyl- (1-6C)alkoxy, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkoxy, amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, halogeno- (2-6C)alkylamino, hydroxy-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, cyano-
(1-6C)alkylamino, carboxy-(1-6C)alkylamino, (1-6C)alkoxycarbonyl-(1-6C)alkylamino,
\ carbamoyl-(1-6C)alkylamino, N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkylamino, amino-(2-6C)alkylamino, E (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, N-(1-6C)alkyl-halogeno-(1-6C)alkylamino, N-(1-6C)alkyl-hydroxy-(2-6C)alkylamino,
N-(1-6C)alkyl-(1-6C)alkoxy-(2-6C)alkylamino, N-(1-6C)alkyl-cyano-(1-6C)alkylamino,
N-(1-6C)alkyl-carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonyl-
(1-6C)alkylamino, N-(1-6C)alkyl-carbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl- N-(1-6C)alkylcarbamoyl-(1-6C)alkylamino, N-(1-6C)alkyl-N,N-di-[(1-6C)alkyl]carbamoyi- (1-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino- (2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]amino-(2-6C)alkylamino,
halogeno-(2-6C)alkanoylamino, hydroxy-(2-6C)alkanoylamino, (1-6C)alkoxy- - (2-6C)alkanoylamino, cyano-(2-6C)alkanoylamino, carboxy-(2-6C)alkanoylamino, (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino, carbamoyl-(2-6C)alkanoylamino, N-(1-6C)alkylcarbamoyl-(2-6C)alkanoylamino, N,N-di-[(1-6C)alkyl]carbamoyl- (2-6C)alkanoylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino,
di-[(1-6C)alkyi]amino-(2-6C)alkanoylamino, aryl, aryl-(1-6C)alkyl, aryl-(1-6C)alkoxy, aryloxy, arylamino, N-(1-6C)alkyl-arylamino, ary!-(1-6C)alkylamino, N-(1-6C)alkyl-aryl- (1-6C)alkylamino, aroylamino, arylsulphonylamino, N-arylsulphamoyl, aryl- (2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryloxy, heteroaryl- (1-6C)alkoxy, heteroarylamino, N-(1-6C)alkyl-heteroarylamino, heteroaryl-(1-6C)alkylamino,
N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino, heteroarylcarbonylamino, heteroarylsulphonylamino, N-heteroarylsulphamoyl, heteroaryl-(2-6C)alkanoylamino, heteroaryl-(1-6C)alkoxy-(1-6C)alkyl, heteroary!l-(1-6C)alkylamino-(1-6C)alky!, N-(1-6C)alkyl-heteroaryl-(1-6C)alkylamino-(1-6C)alkyl, heterocyclyl, heterocyclyl- (1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy, heterocyclytamino, N-(1-6C)alkyl-
heterocyclylamino, heterocyclyl-(1-6C)alkylamino, N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino, heterocyclylcarbonylamino, heterocyclylsulphonylamino, N-heterocyclylsulphamoyl, heterocyclyl-(2-6C)alkanoylamino, heterocyclyl-(1-6C)alkoxy- (1-6C)alkyl, heterocyclyl-(1-6C)alkylamino-(1-6C)alkyl and N-(1-6C)alkyl-heterocyclyl- (1-6C)alkylamino-(1-6C)alkyl,
and wherein any of the substituents on Q* defined hereinbefore which comprises a CH, group . which is attached to 2 carbon atoms or a CH, group which is attached to a carbon atom may optionally bear on each said CH, or CH, group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alky!]amino and heterocyclyl, and wherein any aryl, heteroaryl or heterocyclyl group in a substituent on Q* may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]Jcarbamoyl,
(2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl}Jamino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkylJamino-(1-6C)alkyl, aryl and aryl-(1-6C)alky]; S or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof.
2. B An amide derivative of the Formula I according to claim 1 wherein Q’ is a heteroaromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur which bears a basic substituent selected from amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, amino-(2-6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]Jamino-(2-6C)alkylamino, amino-(2-6C)alkanoylamino, (1-6C)alkylamino-(2-6C)alkanoylamino, di-{(1-6C)alkyl]amino-(2-6C)alkanoylamino, heteroaryl, heteroaryl-(1-6C)alkyl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl and heterocyclyl-(1-6C)alkoxy, and wherein any heteroary! or heterocyclyl group in a basic substituent on Q* may optionally bear 1 or 2 substituents selected from halogeno, (1-6C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.
3. An amide derivative of the Formula [ according to claim 1 wherein Q’ is a heteroaromatic S- or 6-membered monocyclic ring, a 9- or 10-membered bicyclic ring or a 13- or 14-membered tricyclic ring each with up to five ring heteroatoms : selected from oxygen, nitrogen and sulphur which optionally bears 1, 2 or 3 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, nitro, amino, carboxy, (1-6C)alkyl, . (1-6C)alkoxy, (1-3C)alkylenedioxy, (1-6C)alkylamino, di-[(1-6C)alkyi]amino and (1-6C)alkoxycarbonyl. 4, An amide derivative of the Formula I according to claim 1 wherein R* is amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, amino-(1-6C)alkyl,
(1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, amino-(2-6C)alkoxy, ~ (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyljamino-(2-6C)alkoxy, amino- (2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino- (2-6C)alkylamino, N-(1-6C)alkyl-amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino- (2-6C)alkylamino, N-(1-6C)alkyl-di-[(1-6C)alkyl]Jamino-(2-6C)alkylamino, pyridyl, - imidazolyl, pyridyl-(1-6C)alkyl, imidazolyl-(1-6C)alkyl, pyridyl-(1-6C)alkoxy, imidazolyl- (1-6C)alkoxy, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 4-(1-6C)alkylpiperazinyl, homopiperazinyl, 4-(1-6C)alkylthomopiperazinyl, 4-(2-6C)alkanoylpiperazinyl, pyrrolidinyl- (1-6C)alkyl, piperidinyl-(1-6C)alkyl, morpholinyl-(1-6C)alkyl, piperazinyl-(1-6C)alkyl, 4-(1-6C)alkylpiperazinyl-(1-6C)alkyl, homopiperazinyl-(1-6C)alkyl, 4-(1-6C)alkylhomopiperazinyl-(1-6C)aikyl, 4-(2-6C)alkanoylpiperazinyl-(1-6C)alkyl, pyrrolidinyloxy, piperidinyloxy, 1-(1-6C)alkylpiperidinyloxy, pyrrolidinyl-(2-6C)alkoxy, piperidinyl-(2-6C)alkoxy, morpholinyl-(2-6C)alkoxy, piperazinyl-(2-6C)alkoxy, 4-(1-6C)alkylpiperazinyl-(2-6C)alkoxy or 4-(2-6C)alkanoylpiperazinyl-(2-6C)alkoxy.
5. An amide derivative of the Formula I according to claim 1 wherein R’ is methyl, ethyl, chloro or bromo; misQorl; R' is hydroxy, fluoro, chloro, bromo, trifluoromethyl, cyano, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino or diethylamino; pis 0; R* is amino, methylamino, ethylamino, dimethylamino, diethylamino, methylaminomethyl, cthylaminomethyl, dimethylaminomethyl, diethylaminomethy!, 2-aminoethoxy, 3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy, 3-ethylaminopropoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, B 3-dimethylaminopropoxy, 3-diethylaminopropoxy, pyridyl, pyridylmethyl, pyridylmethoxy, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl, piperazinylmethyl, 4-methylpiperazinylmethyl, 4-acetylpiperazinylmethyl, piperidinyloxy, 1-methylpiperidinyloxy, 2-(pyrrolidinyl)ethoxy, 3-(pyrrolidinyl)propoxy, 2-(piperidinyl)ethoxy, 3-(piperidinyl)propoxy, 2-(morpholinyl)ethoxy,
3-(morpholinyl)propoxy, 2-(piperazinyl)ethoxy, 3-(piperazinyl)propoxy, 2-(4-methylpiperazinyl)ethoxy, 3-(4-methylpiperazinyl)propoxy, 2-(4-acetylpiperazinyl)ethoxy or 3-(4-acetylpiperazinyl)propoxy; q is 0; and _ 5 Q’is furyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, ~ pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiophenyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl or naphthyridinyl which optionally bears I or 2 substituents selected from hydroxy, fluoro, chloro, trifluoromethyl, cyano, amino, methyl, 10 ethyl, methoxy, ethoxy, methylenedioxy, methylamino, ethylamino, dimethylamino, diethylamino, aminomethyl, methylaminomethyl, ethylaminomethyl, dimethylaminomethyl, diethylaminomethyl, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 2-ethoxyethoxy, 3-methoxypropoxy, 3-ethoxypropoxy, 2-aminoethoxy, 3-aminopropoxy, 2-methylaminoethoxy, 2-ethylaminoethoxy, 3-methylaminopropoxy, 3-ethylaminopropoxy, 15 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, pyridyl, pyridylmethyl, pyridylmethoxy, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl, piperazinylmethyl, 4-methylpiperazinylmethyl, . 4-acetylpiperazinylmethyl, piperidinyloxy, 1-methylpiperidinyloxy, 2-(pyrrolidinyl)ethoxy, 20 3-(pyrrolidinyl)propoxy, 2-(piperidinyl)ethoxy, 3-(piperidinyl)propoxy, 2-(morpholinyl)ethoxy, 3-(morpholinyl)propoxy, 2-(piperazinyl)ethoxy, 3-(piperazinyl)propoxy, 2-(4-methylpiperazinyl)ethoxy, 3-(4-methylpiperazinyl)propoxy, 2-(4-acetylpiperazinyl)ethoxy and 3-(4-acetylpiperazinyl)propoxy; or a pharmaceutically-acceptable salt thereof. 25
6. An amide derivative of the Formula I according to claim 1 wherein R’ is methyl; - mis 0 orm is 1 and R' is hydroxy, fluoro, chloro, amino, methyl, methoxy, methylamino or dimethylamino; eachofpandqisO;
R* is located at the 3- or 4-position and is selected from dimethylaminomethyl,
- diethylaminomethyl, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 3-dimethylamino-2-hydroxypropoxy, 3-diethylamino-2-hydroxypropoxy, 2-aminoethylamino, 3-aminopropylamino,
4-aminobutylamino, 3-methylaminopropylamino, 2-dimethylaminoethylamino, = 2-diethylaminoethylamino, 3-dimethylaminopropylamino, 4-dimethylaminobutylamino, 3-amino-2-hydroxypropylamino, 3-dimethylamino-2-hydroxypropylamino, N-(2-dimethylaminoethyl)-N-methylamino, N-(3-dimethylaminopropyl)-N-methylamino, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 4-methylpiperazin-1-yl,
4-ethylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl, 4-methylhomopiperazin-1-yl, piperazin-1-yimethyl, 4-methylpiperazin-1-ylmethyl, 4-methylhomopiperazin-1-yimethyl, morpholinomethyl, 3-aminopyrrolidin-1-ylmethyl, 3-hydroxypyrrolidin-1-ylmethyl, 4-(2-hydroxyethyl)piperazin-1-ylmethyl, piperidin-4-yloxy, I-methylpiperidin-4-yloxy, 1-benzylpiperidin-4-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,
2-piperidinoethoxy, 3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-hydroxy-3-pyrrolidin-1-ylpropoxy, 2-hydroxy- 3-piperidinopropoxy, 2-hydroxy-3-morpholinopropoxy, piperidin-4-ylamino, 1-methylpiperidin-4-ylamino, 1-benzylpiperidin-4-ylamino, 2-pyrrolidin-1-ylethylamino,
3-pyrrolidin-1ylpropylamino, 2-morpholinoethylamino, 3-morpholinopropylamino, 2-piperidinoethylamino, 3-piperidinopropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, 2-(4-methylpiperazin-1-yl)ethylamino, 3-(4-methylpiperazin-1-yl)propylamino, 2-(1-methylpyrrolidin-2-yl)ethylamino, 3-(1-methylpyrrolidin-2-yl)propylamino, 2-dimethylaminoethylaminomethyl,
3-dimethylaminopropylaminomethyl, 3-dimethylamino-2,2-dimethylpropylaminomethyl,
RB 2-(1-methylpyrrolidin-2-ylethyl)aminomethyl, 3-pyrrolidin-1-ylpropylaminomethyl, 2-morpholinoethylaminomethyl, 3-morpholinopropylaminomethyl, 2-piperazin- 1-ylethylaminomethyl, 3-(4-methylpiperazin-1-ylpropyl)aminomethyl and 2-pyridylmethoxy; and Q? is 2-pyridyl, 3-pyridyl or 4-pyridyl which bears a substituent selected from pyrrolidin-1-yl, 3-hydroxypyrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, morpholino,
piperidino, 4-hydroxypiperidin-1-yl and piperazin-1-yl;
or a pharmaceutically-acceptable salt thereof.
7. An amide derivative of the Formula I according to claim 1 wherein R’ is methyl; 5S misOormis1andR!'is nitro or amino; . oT } eachof pand q is 0; R* is located at the 3- or 4-position and is selected from diethylaminomethyl, N-(3-dimethylaminopropyl)-N-methylamino, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl, pyrrolidin-1-ylmethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, homopiperazin-1-ylmethyl, 4-methylhomopiperazin-1-ylmethyl, 3-aminopyrrolidin- 1-ylmethyl, 3-hydroxypyrrolidin-1-ylmethyl, 4-(2-hydroxyethyl)piperazin-1-ylmethyl, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin- 4-yloxy, N-ethylpiperidin-4-yloxy, N-isopropylpiperidin-4-yloxy, homopiperidin-4-yloxy, : 15 N-methylhomopiperidin-4-yloxy, 3-pyrrolidin-1-ylpropylaminomethyl, 2-(1-methylpyrrolidin-2-ylethyl)aminomethyl, 2-morpholinoethylaminomethyl, 3-morpholinopropylaminomethyl, 3-(4-methylpiperazin-1-ylpropyl)aminomethyl, pyrid-2-ylmethoxy, thiazol-4-ylmethoxy and 2-methylthiazol-4-ylmethoxy; and Q? is 2-pyridyl, 3-pyridyl or 4-pyridyl which bears a substituent selected from pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, morpholino and piperidino, and wherein any of the 4 last- named substituents may optionally bear 1 or 2 methyl groups, or Q? is 2- or 4-dibenzofuranyl; or a pharmaceutically-acceptable salt thereof.
8. An amide derivative of the Formula I according to claim 1 wherein R? is methyl; R mis Oormis 1 and R'is nitro or amino; each of pand q is 0; R‘ is located at the 3- or 4-position and is selected from diethylaminomethyl, N-(3-dimethylaminopropyl)-N-methylamino, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl, pyrrolidin-1-ylmethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl,
homopiperazin-1-ylmethyl, 4-methylhomopiperazin-1-ylmethyl, 3-aminopyrrolidin- 1-ylmethyl, 3-hydroxypyrrolidin-1-ylmethyl, 4-(2-hydroxyethyl)piperazin-1-ylmethyl, pyrrolidin-3-yloxy, piperidin-4-yloxy, 3-pyrrolidin-1-ylpropylaminomethyl, 2-(1-methylpyrrolidin-2-ylethyl)aminomethyl, 2-morpholinoethylaminomethyl, 3-morpholinopropylaminomethyl, 3-(4-methylpiperazin-1-ylpropyl)aminomethy! or = pyrid-2-ylmethoxy; and Q? is 2-pyridyl, 3-pyridyl or 4-pyridyl which bears a substituent selected from pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl, morpholino and piperidino; or a pharmaceutically-acceptable salt thereof.
9. An amide derivative of the Formula I according to claim 1 wherein R’ is methyl; each of m, p and q is 0; R* is located at the 3- or 4-position and is selected from diethylaminomethyl, 4-methylpiperazin-1-yl, morpholinomethyl, piperazin-1-ylmethyl, 4-methylpiperazin- 1-ylmethyl, 4-methylhomopiperazin-1-ylmethyl, 3-hydroxypyrrolidin-1-ylmethyl, pyrrolidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, N-isopropylpiperidin- 4-yloxy, N-methylhomopiperidin-4-yloxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-dimethylamino-2,2-dimethylpropylaminomethyl N-(3-dimethylaminopropyl)- N-methylaminomethyl, 3-morpholinopropylaminomethyl and 2-methylthiazol-4-ylmethoxy; and Q’ is 4-pyridyl which bears a substituent selected from morpholino, piperidino, 3-methylpiperidin-1-yl and homopiperidin-1-yl, or Q? is 4-dibenzofuranyl; or a pharmaceutically-acceptable salt thereof.
10. An amide derivative of the Formula I according to claim 1 selected from :- K N-{4-methyl-3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]phenyl} furan-2-carboxamide, N-{4-methyl-3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]phenyl}isoxazole- 5-carboxamide, N-[3-(4-diethylaminomethylbenzamido)-4-methylphenyl]-2-morpholinopyridine- 4-carboxamide,
N-{3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]-4-methylphenyl}- 2-pyrrolidin-1-ylpyridine-4-carboxamide, N-{3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]-4-methylphenyl} -2-morpholinopyridine- 4-carboxamide,
__ ... .. _ 5 N-{3-[3-(4-methylhomopiperazin-1-ylmethyl)benzamido]-4-methylphenyl}- ~~ 2-morpholinopyridine-4-carboxamide, N-{3-{4-(4-methylhomopiperazin-1-ylmethyl)benzamido]-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide, N-[3-(3-piperazin-1-ylmethylbenzamido)-4-methylphenyl]-2-morpholinopyridine- 4-carboxamide, N-{3-[4-(3-hydroxypyrrolidin-1-ylmethyl)benzamido]-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide, N-{3-[3-(3-pyrrolidin-1-ylpropylaminomethyl)benzamido]-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide,
. 15 N-{3-[4-(3-morpholinopropylaminomethyl)benzamido]-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide, N-[3-(3-diethylaminomethylbenzamido)-4-methylphenyl]-2-morpholinopyridine- 4-carboxamide, N-[3-(4-diethylaminomethylbenzamido)-4-methylphenyl]-5-morpholinopyridine- 3-carboxamide, N-[3-(4-diethylaminomethylbenzamido)-4-methylphenyl}-2-piperidinopyridine- 4-carboxamide, N-{3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]-4-methylphenyl}-2-(3-methylpiperidin- 1-yl)pyridine-4-carboxamide, N-{3-[3-(4-methylpiperazin-1-ylmethyl)benzamido}-4-methylphenyl}-2-homopiperidin- 1-ylpyridine-4-carboxamide, N-[4-methyl-3-(4-morpholinomethylbenzamido)phenyl]-2-morpholinopyridine- - 4-carboxamide, N-{3-[3-(3-dimethylamino-2,2-dimethylpropylaminomethyl)benzamido}-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide,
N-{3-[4-(3-dimethylamino-2,2-dimethylpropylaminomethyl)benzamido]-4-methylpheny!}- 2-morpholinopyridine-4-carboxamide, N-(3-{4-[N-(3-dimethylaminopropyl)-N-methylaminomethyl]benzamido } -4-methylphenyl)- 2-morpholinopyridine-4-carboxamide, N-[4-methyl-3-(3-piperidin-4-yloxybenzamido)phenyl]-2-morpholinopyridine- = 4-carboxamide, N-[4-methyl-3-(3-pyrrolidin-3-yloxybenzamido)phenyl]-2-morpholinopyridine- 4-carboxamide, N-{3-[3-(N-methylhomopiperidin-4-yloxy)benzamido]-4-methylphenyl}- 2-morpholinopyridine-4-carboxamide, N-(3-{3-[2-(N-methylpyrrolidin-2-yl)ethoxy]benzamido} -4-methylphenyl)- 2-morpholinopyridine-4-carboxamide, N-{4-methy!-3-[4-(2-methylthiazol-4-ylmethoxy)benzamido]phenyl}-2-morpholinopyridine- 4-carboxamide and N-{3-[3-(4-methylpiperazin-1-ylmethyl)benzamido]-4-methylphenyl}dibenzofuran- 4-carboxamide; or a pharmaceutically-acceptable salt thereof.
11. A process for the preparation of an amide derivative of the Formula [, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, according to claim which comprises :- (a) reacting an aniline of the Formula II (RY, o R3 CE
NH. II 2 : with an acid of the Formula III, or a reactive derivative thereof, ’s HO,C — (CHy)q — Q2 II under standard amide bond forming conditions, wherein variable groups are as defined in claim 1 and wherein any functional group is protected if necessary, and:
i) removing any protecting groups; and (1) optionally forming a pharmaceutically-acceptable salt or in-vivo-cleavable ester; (b) reacting an acid of the Formula V, or an activated derivative thereof, — RY, o | - s Re EK, \4 with an aniline of the Formula VII R3 Kr (R?), ’ HN H N 0 MCHy,— a2 vi : under standard amide bond forming conditions, wherein variable groups are as defined in claim 1 and wherein any functional group is protected, if necessary, and:
6) removing any protecting groups; and
(ii) optionally forming a pharmaceutically-acceptable salt or in-vivo-cleavable : ester;
" (c) for the preparation of a compound of the Formula I wherein R', R or a substituent on Q? is (1-6C)alkoxy or substituted (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylamino,
di-[(1-6C)alkyl}amino or substituted (1-6C)alkylamino, the alkylation, conveniently in the presence of a suitable base, of an amide derivative of the Formula I wherein R!, R* or a substituent on Q? is hydroxy, mercapto or amino as appropriate;
(d) for the preparation of a compound of the Formula I wherein a substituent on Qis amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, substituted (1-6C)alkylamino, substituted
N-(1-6C)alkyl-(2-6C)alkylamino or a N-linked heterocyclyl group, the reaction, conveniently
: in the presence of a suitable base, of an amide derivative of the Formula I wherein a substituent on Q” is a suitable leaving group with an appropriate amine; (¢) for the preparation of a compound of the Formula I wherein R', R* or a substituent on Q’ is (1-6C)alkanoylamino or substituted (2-6C)alkanoylamino, the acylation of a compound
PCT/GB99/03144 of the Formula I wherein R', R* or a substituent on Q? is amino; ® for the preparation of a compound of the Formula I wherein R' or a substituent on Q? is (1-6C)alkanesulphonylamino, the reaction of a compound of the Formula I wherein R! or a substituent on Q? is amino with a (1-6C)alkanesulphonic acid, or an activated derivative thereof: or (2) for the preparation of a compound of the Formula [ wherein R' or a substituent on Q? is carboxy, carboxy-(1-6C)alkyl, carboxy-(1-6C)alkoxy, carboxy-(1-6C)alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)alkylamino or carboxy-(2-6C)alkanoylamino, the cleavage of a compound of the Formula I wherein R' or a substituent on Q? is (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl-(1-6C)alkyl, (1 -6C)alkoxycarbonyl~( 1-6C)alkoxy, (1-6C)alkoxycarbonyl-(1-6C)alkylamino, N~(1-6C)alkyl-(1-6C)alkoxycarbonyl- (1-6C)alkylamino or (1-6C)alkoxycarbonyl-(2-6C)alkanoylamino as appropriate.
12. A pharmaceutical composition which comprises an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.
13. The use of an amide derivative of the Formula I, or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof, according to claim 1 in the manufacture of a medicament for use in the treatment of medical conditions mediated by cytokines.
14. A substance or composition for use in method of treatment of medical conditions mediated by cytokines, said substance or composition comprising a compound as claimed in claim 1, and said method comprising administering said substance or composition.
15. A compound according to claim 1, substantially as herein described and illustrated.
16. A process according to claim 11, substantially as herein described and illustrated. AMENDED SHEET 2002 -01- 18
- 133 - PCT/GB99/03144
17. A composition according to claim 12, substantially as herein described and illustrated.
18. Use according to claim 13, substantially as herein described and illustrated.
19. A substance or composition for use in a method of treatment according to claim 14, substantially as herein described and illustrated.
20. A new compound, a new composition, new use of a compound as claimed in claim 1, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET 2002 -mM- 18
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9820770.7A GB9820770D0 (en) | 1998-09-25 | 1998-09-25 | Amide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200102185B true ZA200102185B (en) | 2002-06-18 |
Family
ID=10839368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200102185A ZA200102185B (en) | 1998-09-25 | 2001-03-15 | Benzamide derivatives and their use as cytokine inhibitors. |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9820770D0 (en) |
ZA (1) | ZA200102185B (en) |
-
1998
- 1998-09-25 GB GBGB9820770.7A patent/GB9820770D0/en not_active Ceased
-
2001
- 2001-03-15 ZA ZA200102185A patent/ZA200102185B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB9820770D0 (en) | 1998-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU761291B2 (en) | Amide derivatives | |
CA2368097C (en) | Amide derivatives of 3,4-dihydroquinazolinone compounds useful as cytokine inhibitors | |
US6432949B1 (en) | Amide derivatives useful as inhibitors of the production of cytokines | |
AU761361B2 (en) | Benzamide derivatives and their use as cytokine inhibitors | |
AU772293B2 (en) | Pyrimidine derivatives | |
ZA200102185B (en) | Benzamide derivatives and their use as cytokine inhibitors. | |
ZA200106857B (en) | Amide derivatives. | |
ZA200006030B (en) | Benzamide derivatives for the treatment of diseases mediated by cytokines. | |
MXPA01009308A (en) | Amide derivatives |